BHCM
DFTX

Brevan Howard Capital Management’s Definium Therapeutics DFTX Stock Holding History

Brevan Howard Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4M Buy
211,488
+200,374
+1,803% +$3.4M 0.04% 320
2025
Q4 		$149K Buy
+11,114
New +$138K ﹤0.01% 1633
2024
Q2 		– Sell
-10,649
Closed -$100K – 1272
2024
Q1 		$100K Buy
+10,649
New +$60.7K ﹤0.01% 894

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brevan Howard Capital Management's DFTX Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Definium Therapeutics (DFTX) stake by 1,803% in Q1 2026, buying an estimated $3.4M and bringing the position to 211,488 shares worth $4M. The position accounts for 0.04% of the portfolio, ranked #320.

Brevan Howard Capital Management first reported a position in DFTX in Q1 2024 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Brevan Howard Capital Management held 211,488 shares of Definium Therapeutics worth $4M as of Q1 2026.
  • Brevan Howard Capital Management bought 200,374 Definium Therapeutics shares in Q1 2026, an estimated $3.4M.
  • Definium Therapeutics made up 0.04% of Brevan Howard Capital Management's portfolio in Q1 2026, its #320 holding.
  • Brevan Howard Capital Management first reported a position in Definium Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.